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Summary
Background The population prevalence, clinical characteristics, and associations for Rome IV functional dyspepsia are 
not known. Following the publication of the Rome IV criteria for functional gastrointestinal disorders, we aimed to 
assess the prevalence, characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults 
across the USA, Canada, and the UK.
Methods We sent an internet-based cross-sectional health survey to adults in the general population of 
three English-speaking countries: the USA, Canada, and the UK. We used quota-based sampling to generate 
demographically balanced and population-representative samples. Individuals were invited to complete an online 
questionnaire on general health, without mention that the purpose of this survey was to examine gastrointestinal 
symptoms. We excluded participants who failed two attention-test questions or were excessively inconsistent on the 
three gastrointestinal questions that were presented twice in the survey for this particular purpose. The survey enquired 
about demographics, health-care visits, medications, somatisation, quality of life, and symptom-based criteria for 
Rome IV functional dyspepsia as well as for irritable bowel syndrome (IBS) and functional heartburn. We made 
subsequent comparisons between participants with Rome IV functional dyspepsia and controls without dyspepsia. 
The primary objective was to identify participants who fulfilled symptom-based criteria for Rome IV functional 
dyspepsia and categorise them into postprandial distress syndrome, epigastric pain syndrome, or overlapping subtypes.
Findings 6300 general population adults completed the health survey; 2100 each from the USA, Canada, and the UK. 
369 responses were deemed inconsistent, leaving data for 5931 adults. Rome IV functional dyspepsia was significantly 
more prevalent in the USA (232 [12%] of 1949) than in Canada (167 [8%] of 1988) and the UK (152 [8%] of 1994; 
p<0·0001). The subtype distribution was 61% postprandial distress syndrome, 18% epigastric pain syndrome, and 
21% overlapping variant with both syndromes; this pattern was similar across the countries. Participants with 
functional dyspepsia had significantly greater health impairment and health-care usage than those without dyspepsia. 
Participants with the overlapping variant showed greater somatisation and poorer quality-of-life scores than did 
individuals with either postprandial distress syndrome or epigastric pain syndrome alone. In multivariate analysis, 
independent factors associated with all functional dyspepsia subtypes included worsening quality of life and the 
presence of symptoms compatible with functional heartburn and IBS, with functional heartburn and IBS having the 
strongest association with overlapping postprandial distress syndrome and epigastric pain syndrome. Notably, 
somatisation showed a positive association with postprandial distress syndrome and the overlapping variant, and use 
of antidepressants showed a negative association with postprandial distress syndrome.
Interpretation Approximately 10% of the adult population fulfils symptom-based criteria for Rome IV functional 
dyspepsia and incurs considerable associated health impairment. The functional dyspepsia subtypes show differing 
associations, suggesting differences in pathophysiological processes or influences.
Funding The Rome Foundation, the US National Institute of Diabetes and Digestive and Kidney Diseases, the Swedish 
Medical Research Council, AFA Insurance, Ferring Pharmaceuticals, and the Faculty of Medicine, University of 
Gothenburg, Gothenburg, Sweden.
Introduction
Dyspepsia is a constellation of symptoms referable to the 
gastroduodenal region of the upper gastrointestinal 
tract.1 It has been reported to affect an estimated 21% of 
the general population, with prevalence varying from 
29·5% when using broad historical definitions (ie, any 
upper gastrointestinal symptoms, including reflux), to 
7·6% when using the symptoms defined by the Rome III 
committee (ie, epigastric pain or burning [or both], 
postprandial fullness or early satiety [or both]).2 More 
than 70% of people with dyspepsia undergoing endoscopy 
will have no identifiable organic pathology to account for 
their symptoms and will be diagnosed as having 
functional dyspepsia,3 which can be further subgrouped 
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into epigastric pain syndrome, postprandial distress 
syndrome, or the overlapping variant.4 Furthermore, 
functional dyspepsia represents a substantial health 
burden, being associated with increased health-care 
usage,5,6 psychological distur bances,7–9 somatisation,8,10 
impaired quality of life,11 and presence of overlapping 
functional gastrointestinal disorders such as irritable 
bowel syndrome (IBS) and heartburn.12,13
Limitations remain in research into functional 
dyspepsia. First, the prevalence of functional dyspepsia, 
as defined b y t he R ome c riteria, h as n ot b een 
simultaneously evaluated across multiple countries.2 
Rather, previous studies using Rome I to III criteria 
have been limited to evaluations within single 
communities and, when pooled within the domains of 
their respective criteria, have shown wide prevalence 
ranges and substantial heterogeneity, with differences 
noted in sample size, symptom duration, and methods 
used to collect symptom data.2 Furthermore, within 
the context of Rome III functional dyspepsia, a 
meta-analysis found only seven studies, of which six 
were from Asia and one was from the USA, with 
prevalence ranging from 1·8% to 17·5%;2 clinical and 
epidemiological differences i n f unctional d yspepsia 
have been noted between Asia compared with Europe 
and North America.14 Second, an overarching pers-
pective of the effects of functional dyspepsia on 
multiple health parameters has not been concurrently 
evaluated, but rather limited to comparisons against 
single or few health measurements.5–13 Third, data are 
conflicting with regard to functional dyspepsia and 
somatisation; one group suggested that the over-
lapping variant is associated with worse somatisation 
than postprandial distress syndrome or epigastric 
pain syndrome alone,8 but another did not replicate 
these findings.10
The publication of the Rome IV criteria for functional 
gastrointestinal disorders provides an opportunity to 
address these uncertainties in a systematic and 
homogeneous manner, using the most contemporaneous 
definition.15–17 We analysed data from a large cross-sectional 
population-based survey across three English-speaking 
countries with the aim to further understand the 
epidemiology and clinical associations of Rome IV 
functional dyspepsia and its subtypes, with participants 
without dyspepsia as comparative controls.
Methods 
Study design and participants
We commissioned Qualtrics (Provo, UT, USA), a global 
market survey company, in 2015 to provide a nationally 
representative general population sample of adults 
from three English-speaking countries: the USA, 
Canada, and the UK. Quota-based sampling was used 
Research in context
Evidence before this study
Functional dyspepsia is associated with overlapping functional 
gastrointestinal disorders, poor quality of life, and increased 
health-care usage. Although functional dyspepsia is perceived to 
be common, its prevalence has shown wide variations, even 
within similar geographical regions, due to differences in sampling 
methods and the criteria used to define its presence. We searched 
PubMed and our own files for articles relevant to functional 
dyspepsia published up to Sept 1, 2017, with the search terms 
“dyspepsia”, “functional dyspepsia”, “epigastric pain syndrome”, 
and “postprandial distress syndrome”, without a start date or 
language restrictions. We found no articles that assessed the 
prevalence of functional dyspepsia across multiple communities 
using any of the criteria proposed by the Rome Foundation, an 
international panel of experts working in the field of functional 
gastrointestinal disorders for almost 30 years. Furthermore, the 
association between somatisation and functional dyspepsia has 
been limited to a few studies that showed conflicting results. 
Following the publication of the Rome IV criteria for functional 
gastrointestinal disorders, we aimed to assess the prevalence, 
characteristics, and associations for symptom-based Rome IV 
functional dyspepsia in adults across the USA, Canada, and the UK.
Added value of our study
To our knowledge, we report for the first time that 
approximately 10% of the adult population from the USA, 
Canada, and the UK fulfil the Rome IV symptom-based criteria 
for functional dyspepsia. We found that the highest prevalence 
is in the USA (12%), compared with Canada (8%) and the 
UK (8%). The predominant functional dyspepsia subtype in 
each country is postprandial distress syndrome (about 60%), 
followed by a relatively even split between epigastric pain 
syndrome and the overlapping variant. All functional 
dyspepsia subtypes had greater health impairment, including 
somatisation, than those without dyspepsia. We found that 
antidepressants might reduce the association with functional 
dyspepsia, in particular for the postprandial distress 
syndrome variant.
Implications of all the available evidence
Awareness of the epidemiological scale of Rome IV functional 
dyspepsia, and its detrimental effect on general health and 
wellbeing, will aid clinical service and research provision 
planning. This is pertinent given that current international 
guidelines acknowledge the lack of effective therapy for 
functional dyspepsia. Furthermore, current guidelines for 
dyspepsia largely focus on the epigastric pain variant and our 
study suggests that the predominant subtype is the 
postprandial distress syndrome variant, for which therapies are 
arguably even more unsatisfactory.
to generate demographically balanced and population-
representative samples with regard to age, sex, and 
education. Extensive details regarding the geographical 
distribution (by state, province or territory, or 
government region) and demographic profile of 
participants, and how closely they resemble the general 
population, have been described elsewhere.18 Before 
data collection started, the study was reviewed by the 
Institutional Review Board (IRB) at the University of 
North Carolina (Chapel Hill, NC, USA), and deemed 
IRB exempt because all study participants were 
anonymous to the investigators. The study was done in 
accordance with the STROBE statement.
Procedures
Individuals were invited to complete an online 
questionnaire on general health, without mention that 
the purpose of this survey was to examine gastrointestinal 
symptoms. The comprehensive questionnaire collected 
information about demographic characteristics (age, 
gender, race, relationship status, and country of 
residence), medication (antiemetic, acid-suppressive 
medication, analgesics, and antidepressants), health-care 
visits, somatisation,19 quality of life,20 and the presence 
of Rome IV functional gastrointestinal disorders.17 
Further details on the questionnaires have been described 
previously.18
Multiple quality assurance methods were built into 
the survey to minimise bias and poor quality reporting.18 
These included the software detecting missing answers 
for any applicable question and ensuring participants 
completed these before being allowed to proceed. 
Furthermore, taking into consideration the possibility 
of inconsistent responders, we excluded participants 
who failed two attention-test questions or were 
excessively inconsistent on the three gastrointestinal 
questions that were presented twice in the survey for 
this particular purpose.18
Outcomes
The primary outcome was to identify participants 
who fulfilled symptom-based criteria for Rome IV 
functional dyspepsia and to categorise them into 
postprandial distress syndrome, epigastric pain 
syndrome, or overlapping subtypes.21 We did not ask 
participants about previous endoscopies and, given the 
study design, could not perform endoscopies. The 
definition of epigastric pain syndrome was based on at 
least 1 day per week of bothersome epigastric pain, 
burning, or both. The definition of postprandial 
distress syndrome was based on at least 3 days per 
week of bothersome postprandial fullness, early satiety, 
or both. Those with the overlapping variant fulfilled 
criteria for both. Furthermore, the symptoms had to be 
present for the last 3 months with onset at least 6 
months previously.21 All individuals in the population 
who did not meet Rome IV symptom-based criteria for 
functional dyspepsia were used as control participants 
in the analyses.
In those with and without functional dyspepsia, we 
also identified the proportion of participants who had 
symptoms compatible with functional heartburn and 
IBS in accordance with the Rome IV criteria.22,23
Figure 1: Population prevalence of Rome IV functional dyspepsia and subtypes using symptom-based criteria
Postprandial distress syndrome



















Age (years) 47·8 (17·2) 43·8 (16·2) <0·0001
Female 2587 (48%) 331 (60%) <0·0001
White 3882 (72%) 389 (71%) 0·44
Relationship status
Single 1591 (30%) 161 (29%) 0·90
Married or cohabiting 2997 (56%) 305 (55%) 0·86
Divorced 551 (10%) 61 (11%) 0·54
Widowed 241 (5%) 24 (4%) 0·89
Symptom scores
PHQ-12 somatisation score 4·4 (3·5) 8·8 (4·4) <0·0001
Number of somatic symptoms 3·5 (2·5) 6·2 (2·6) <0·0001
SF8-PCS 49·9 (9·3) 41·8 (11·3) <0·0001
SF8-MCS 49·9 (10·3) 40·4 (12·7) <0·0001
Overlapping FGIDs
IBS 167 (3%) 174 (32%) <0·0001
Functional heartburn 40 (<1%) 67 (12%) <0·0001
Health-care usage
Seen doctor for gastrointestinal 
health problems
1131 (21%) 240 (44%) <0·0001
More than once yearly 
health-care visits
3003 (56%) 404 (73%) <0·0001
Medication taken at least once a week
Antiemetic 121 (2%) 84 (15%) <0·0001
Acid-suppressive medication 905 (17%) 250 (45%) <0·0001
Analgesic 1450 (27%) 287 (52%) <0·0001
Antidepressant 653 (12%) 140 (25%) <0·0001
Any of the above medication 2153 (40%) 395 (72%) <0·0001
Data are mean (SD) or n (%). PHQ-12=Patient Health Questionnaire-12 somatic 
symptom scale. SF8-PCS=short form-8 quality-of-life form-physical component 
score. SF8-MCS=SF8-mental component score. FGIDs=functional gastrointestinal 
disorders. IBS=irritable bowel syndrome.
Table 1: Univariate analysis comparing participants without dyspepsia 
with those with Rome IV functional dyspepsia
Statistical analysis
We did statistical analyses using SPSS version 21.0, with 
p values of 0·05 or less deemed to be significant. There 
were no missing data because the online questionnaire 
required participants to complete each applicable 
question before being allowed to move on to the next 
step. We determined the prevalence and characteristics of 
the overall population, those with and without functional 
dyspepsia, and the functional dyspepsia subtypes. 
We summarised categorical variables by descriptive 
statistics, including total numbers and percentages, with 
comparisons between groups per formed using the χ² test. 
We summarised continuous variables by mean and 
SD, with differences b etween t wo i ndependent g roups 
compared using the unpaired Student’s t test. For 
comparison of continuous data between multiple groups 
we used the one-way analysis of variance. We did post-hoc 
testing using Bonferroni correction.
We did binary logistic regression to identify independent 
associations for functional dyspepsia (and its individual 
subtypes) against controls without dyspepsia. All 
independent variables were considered for analysis in the 
regression model, but before their entry we assessed for 
multicollinearity using linear regression and checked for 
a variance inflation factor cutoff of  greater than 3.  Th is 
revealed a strong multicollinearity between number of 
somatic symptoms and Patient Health Questionnaire 
(PHQ-12) somatisation score (variance inflation 
factor >10), and as a result, the number of somatic 
symptoms was subsequently omitted from the binary 
logistic regression model. Otherwise, the following 
independent predictor variables that might be associated 
with functional dyspepsia were entered in one block: age, 
female sex, white race, relationship status, country 
of residence, health-care visits, medication, PHQ-12 
somatisation scores, mental and physical quality-of-life 
scores, and presence of symptoms compatible with IBS 
and functional heartburn. These data were presented 
using adjusted odds ratios (AORs) and 95% CIs.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had access to all data 
in the study and had the final r esponsibility f or t he 
decision to submit for publication.
Results
The survey was completed by 6300 individuals: 
2100 from each of the three countries. 369 (5·9%) 
inconsistent responders were excluded from the 
analysis, leaving responses from 5931 individuals in 
the analysis dataset: 1949 from the USA, 1988 from 
Canada, and 1994 from the UK. Mean age was 47·4 
years (SD 17·1), 2918 (49%) participants were female, 
and 4271 (72%) were white. Further characteristics 
have been described elsewhere.18
To assess the prevalence of Rome IV functional 
dyspepsia and its subtypes, we examined the 
5931 participants available for evaluation. 5380 (91%) did 
not meet symptom-based criteria for Rome IV functional 
dyspepsia and were classed as controls. The remaining 
551 (9%) participants within the population fulfilled 
symptom-based criteria for Rome IV functional 
dyspepsia, with 339 (6%) having postprandial distress 
syndrome, 97 (2%) having epigastric pain syndrome, and 
115 (2%) having the overlapping variant.
Rome IV functional dyspepsia was significantly more 
prevalent in the USA (n=232 [12%] of 1949) than in 
Canada (167 [8%] of 1988) and the UK (152 [8%] of 1994; 
p<0·0001). Furthermore, the USA had a higher 
prevalence of postprandial distress syndrome (137 [7%]) 
than Canada (106 [5%]) and the UK (96 [5%]; p=0·007). 
The prevalence of epigastric pain syndrome in the USA 
(36 [2%]), Canada (35 [2%]), and the UK (26 [1%]) was 
similar (p=0·35). However, the USA had an increased 
prevalence of the overlapping variant (59 [3%]) compared 
with Canada (26 [1%]) and the UK (30 [2%]; p<0·0001).
Among participants with Rome IV functional 
dyspepsia, the distribution of subtypes was similar in 
the combined population and across all three countries; 
overall, postprandial distress syndrome was the most 
common subtype, accounting for 61% of all functional 
dyspepsia, with epigastric pain syndrome representing 
18%, and the overlapping variant representing 21% 
(figure 1).
We compared participants with Rome IV functional 
dyspepsia with non-dyspeptic controls (table 1). 
Participants with functional dyspepsia were signifi-
cantly younger and predominantly female compared 
with controls, but a similar proportion were white and 













































relationship statuses were also similar. The prevalence 
of functional dyspepsia was significantly higher 
between the ages of 18 and 34 years (200 [12%] of 1693) 
than in the age groups 35–49 years (131 [10%] of 1365) 
and 50–64 years (154 [9%] of 1642), with the lowest 
prevalence of functional dyspepsia being seen in 
individuals older than 65 years (66 [5%] of 1226; 
p<0·0001). This pattern was seen across both sexes 
(figure 2). Female individuals had a significantly greater 
prevalence of functional dyspepsia than their male 
counterparts across all age groups, except for in those 
older than 65 years, for whom there was no statistical 
difference (p=0·12).
Individuals with functional dyspepsia had significantly 
higher PHQ-12 somatisation scores and number of 
somatic symptoms, worse mental and physical quality 
of life, a higher prevalence of IBS, and were more 
likely to have symptoms compatible with functional 
heart burn, compared with controls (table 1). 
Participants with functional dyspepsia reported greater 
health-care usage compared with controls, with on 
average 73% seeking health care more than once yearly, 
44% consulting for gastrointestinal-related problems, 
and 72% taking dyspepsia-relevant medications (ie, 
antiemetics, acid-suppressive medications, analgesics, 
or antidepres sants). 
We did a comparison of the subtypes of Rome IV 
functional dyspepsia (table 2). There were no 
differences in age, sex, white race, and relationship 
status between the subgroups. However, participants 
with the overlapping variant showed greater 
somatisation and poorer quality-of-life scores than 
individuals with either syndrome alone. Furthermore, 
we analysed PHQ-12 and quality-of-life patterns 
according to country and health-care usage, and found 
that the overlapping group generally had greater 
somatisation (figure 3) and worse quality-of-life scores 
(figure 4) than either syndrome alone.
The prevalence of IBS was also significantly higher 
among those with overlapping postprandial distress 
syndrome and epigastric pain syndrome (72%) than in 
those with epigastric pain syndrome alone (42%) and 
was lowest in those with postprandial distress 
syndrome alone (15%). Furthermore, the prevalence of 
symptoms compatible with functional heartburn was 
also highest among the overlapping group (30%), 
which was significantly higher than the epigastric pain 
syndrome (11%) and postprandial distress syndrome 
alone groups (6%). Those in the overlapping group and 
epigastric pain syndrome alone group had significantly 
more health-care visits, gastrointestinal consultations, 
and dyspepsia-relevant medication than those in the 
postprandial distress syndrome alone group (table 2).
We also examined associations with Rome IV 
functional dyspepsia and subtypes (table 3). Younger age 
was associated with functional dyspepsia, epigastric pain 
syndrome, and the overlapping variant, but not with 
postprandial distress syndrome. Additionally, being from 
the USA was associated with functional dyspepsia, 
postprandial distress syndrome, and the overlapping 
variant, but not with epigastric pain syndrome, compared 
with those from the UK and Canada. Neither sex or 
relationship status had any significant association with 
functional dyspepsia or the subtypes.
The presence of symptoms compatible with functional 
heartburn and IBS was associated with all dyspepsia 
types, with the strongest association seen in those 
with overlapping postprandial distress syndrome and 
epigastric pain syndrome. Similarly, worse physical 
and mental quality-of-life scores were independently 
associated with functional dyspepsia and its subtypes. 
However, increasing somatisation was associated with 
functional dyspepsia, postprandial distress syndrome, 
and the overlapping group, but not with the epigastric 
pain syndrome group (table 3).




Age (years) 45 (16·8) 42·5 (15·6) 41·2 (14·4) 0·068
Female 211 (62%) 52 (54%) 68 (59%) 0·302
White 242 (71%) 70 (72%) 77 (67%) 0·622
Relationship status
Single 91 (27%) 36 (37%) 34 (30%) 0·146
Married or cohabiting 198 (58%) 47 (49%) 60 (52%) 0·164
Divorced 35 (10%) 11 (11%) 15 (13%) 0·721
Widowed 15 (4%) 3 (3%) 6 (5%) 0·748
Symptom scores
PHQ-12 somatisation score 8·0 (4·0) 8·5 (4·3) 11·3 (4·7) <0·0001*†
Number of somatic symptoms 5·8 (2·5) 6·1 (2·6) 7·5 (2·5) <0·0001*†
SF8-PCS 43·8 (11·2) 40·9 (11·2) 37 (10·1) <0·0001*†
SF8-MCS 41·5 (12·8) 40·0 (13·3) 37·6 (11·3) 0·016*
Overlapping FGIDs
IBS 50 (15%) 41 (42%) 83 (72%) <0·0001*†‡
Functional heartburn 21 (6%) 11 (11%) 35 (30%) <0·0001*†
Health-care usage
Seen doctor for gastrointestinal 
health problems
118 (35%) 53 (55%) 69 (60%) <0·0001*‡
More than once yearly health-care 
visits
241 (71%) 70 (72%) 93 (81%) 0·118*
Medication taken at least once a week
Antiemetic 39 (12%) 13 (13%) 32 (28%) <0·0001*†
Acid-suppressing drug 122 (36%) 54 (56%) 74 (64%) <0·0001*‡
Analgesic 156 (46%) 58 (60%) 73 (64%) 0·0001*‡
Antidepressant 71 (21%) 26 (27%) 43 (37%) 0·002*
Any of the above medication 218 (64%) 80 (83%) 97 (84%) <0·0001*‡
Data are mean (SD) or n (%). PDS=postprandial distress syndrome. EPS=epigastric pain syndrome. PHQ-12=Patient 
Health Questionnaire-12 somatic symptom scale. SF8-PCS=short form-8 quality-of-life form-physical component 
score. SF8-MCS=SF8-mental component score. FGIDs=functional gastrointestinal disorders. *Indicates the overlap 
group is significantly different compared with the PDS group. †Indicates the overlap group is significantly different 
compared with the EPS group. ‡Indicates EPS group is significantly different compared with the PDS group. 
Presented p values are across the groups. 
Table 2: Comparison between Rome IV functional dyspepsia subtypes
 
The use of acid-suppressive medications was associated 
with functional dyspepsia and its subtypes. Antiemetic 
use was also associated with functional dyspepsia, 
postprandial distress syndrome, and the overlapping 
variant, but not with epigastric pain syndrome. Notably, 
the use of antidepressants had a negative association with 
functional dyspepsia (AOR 0·63, 95% CI 0·47–0·83; 
p=0·001), and in particular with postprandial distress 
syndrome (0·61, 0·44–0·85; p=0·003). Antidepressants 
might be negatively associated with epigastric pain 
syndrome (0·57, 0·31–1·03; p=0·062) but this association 
was not significant a nd t his w as n ot s een f or t he 
overlapping group (0·72; 0·39–1·33; p=0·299). There was 
no independent association between the number of 
gastroenterology consultations or more than once yearly 
health-care visits and functional dyspepsia or its subtypes.
Discussion
To our knowledge, this is the first study to systematically 
evaluate the population prevalence of functional 
dyspepsia across multiple countries using the Rome 
criteria. We used the Rome IV iteration of the diagnostic 
criteria, which adds further to the novelty of this work. 
Furthermore, the study provides a comprehensive clinical 
and phenotypic profile o f i ndividuals w ith R ome I V 
functional dyspepsia, and identifies i ndependently 
associated factors. This provides a platform for under-
standing the current magnitude of functional dyspepsia, 
differences between the subtypes, and prioritising future 
research efforts.
We have shown that approximately 10% of the adult 
population fulfil Rome IV diagnostic criteria for 
functional dyspepsia, with postprandial distress
syndrome representing approximately 60% of cases, 
followed by a relatively even split between epigastric 
pain syndrome and the overlapping variant. A higher 
prevalence of functional dyspepsia was found in the 
USA, compared with Canada and the UK, which 
remained significant after adjusting for all variables 
within the logistic regression model. Reasons for this 
difference could not be explored within this dataset 
but possible explanations include genetic, cultural, 
socioeconomic, dietary, and environmental factors. A 
systematic review2 has noted that risk factors for 
uninvestigated dyspepsia include smoking, non-steroidal 
anti-inflammatory drug usage, and H elicobacter pylori 
status; however, these associations are modest and their 
overall importance in the cause of symptoms has been 
questioned. Some data also suggests that postprandial 
distress syndrome could be linked with duodenal 
eosinophilia, increased intestinal permeability, and 
neural changes, suggesting a potential infective or 
allergic component to this dyspeptic subtype.24 In line 
with these observations, data from a UK-based 
primary-care registry noted that individuals with 
functional dyspepsia had an increased prevalence of 
atopic disorders such as asthma.25 However, these novel 
findings require replication and future studies 
might benefit from tracking how the prevalence of 
asthma correlates with functional dyspepsia, and in 
particular its postprandial distress syndrome subtype, 
among countries.
We showed that participants with Rome IV functional 
dyspepsia had greater health impairment and health-care 
usage that non-dyspeptic controls. Further more, we 
showed differences in clinical characteristics between 
subtypes of functional dyspepsia. Those with the 
overlapping variant incurred the greatest health 
impairment, as reflected by more frequent use of 
dyspepsia-relevant medications, increased prevalence of 
symptoms compatible with functional heartburn and 
IBS, poorer quality of life, and more severe somatisation. 
Increased somatisation is of particular interest because 
secondary-care studies8,10 have shown conflicting data 
with regard to somatisation in functional dyspepsia. An 
initial study8 from Taiwan suggested that individuals 
with the overlapping variant had greater somatisation 
compared with either syndrome alone, whereas, a study10 
in Canadian patients did not find any significant 
differences. The study in Canadian patients, however, 
was limited to relatively small sample sizes (11 participants 
with epigastric pain syndrome and 33 participants with 
the overlapping variant, compared with 335 participants 
with postprandial distress syndrome). We believe our 
findings help clarify the uncertainty because we analysed 
data from a large sample, while also showing similar 
results irrespective of country or gastrointestinal 
consultation pattern.
Figure 3: PHQ-12 somatisation scores in Rome IV functional dyspepsia subtypes according to (A) country and 
(B) health-care use
Error bars represent 95% CIs. PHQ-12=Patient Health Questionnaire-12 somatic symptom scale. GI=gastrointestinal.
*Overlapping groups had significantly worse scores than postprandial distress syndrome and epigastric pain 
syndrome. †All functional dyspepsia subtypes had significantly worse somatisation scores than controls without






























USA Canada UK No Yes
Country GI health-care consulter
Postprandial distress syndrome Epigastric pain syndrome OverlappingNo dyspepsia
A B
Previous studies have noted a discrepancy in functional 
dyspepsia subtype patterns in the general population 
compared with secondary care.9,26–30 Whereas the 
post prandial distress syndrome variant prevails in the 
community, the overlapping variant is the most 
commonly encountered subtype in hospital settings.9,26–30 
The reasons for this have not been determined, but 
factors that prompt specialist-care referrals for 
dyspepsia include greater symptom severity and 
coexisting functional gastrointestinal disorders,31,32 which 
in accordance with our findings are most commonly 
reported by those with the overlapping variant.
We explored independent factors associated with 
Rome IV functional dyspepsia and its subtypes. Common 
associations across all entities include presence of 
symptoms compatible with functional heartburn and 
IBS, worse mental and physical quality of life, and use of 
acid-suppressive medications. Previous longitudinal 
follow-up studies have noted that poor quality of life 
at baseline can lead to subsequent development of 
functional dyspepsia,33 and this is in line with our 
observations. The presence of other functional 
gastrointestinal disorders increasing the risk of 
functional dyspepsia has also been noted previously;12,13 
however, we emphasised the strength of this association 
according to subtype. We showed that symptoms 
compatible with IBS or functional heartburn exert an 
incremental link towards postprandial distress syndrome, 
then epigastric pain syndrome, with the strongest 
association with overlapping postprandial distress and 
epigastric pain syndromes. This might be due to the 
overlap variant generally endorsing more symptoms 
although the difference seen between epigastric pain 
syndrome and postprandial distress syndrome alone 
might suggest different pathophysiological processes or 
influences. A potential hypothesis is that visceral 
hypersensitivity could be the predominant factor driving 
epigastric pain syndrome—which could explain the 
increased association with other functional gastro-
intestinal disorders seen in this group—whereas 
disturbed gastric accommodation and gastric emptying 
might drive postprandial distress syndrome. However, 
studies evaluating the role of these putative patho-
physiological mechanisms among functional dyspepsia 
subtypes have shown conflicting results.34–38
We noted differences in the relationship of somatisation 
and use of antidepressants on functional dyspepsia. 
Previous studies have shown psychological indices 
such as anxiety, depression, somatisation, and sleep 
disturbances to predispose towards the development of 
postprandial distress syndrome but not epigastric pain 
syndrome.7–9 We also found that somatisation was 
an independent factor positively associated with 
postprandial distress syndrome and the overlapping 
variant, but not for epigastric pain syndrome. 
Furthermore, our study provides novel supporting 
implications that use of antidepressants might 
independently reduce the link with functional dyspepsia, 
in particular for postprandial distress syndrome. 
We speculate that this association might be through 
antidepressants downregulating the dysfunctional 
brain–gut axis, via central inhibitory effects and peripheral 
mediating effects of increasing gastric accommodation, 
enhancing preprandial gastric relaxation, and altering 
gastric emptying rate.39–43 Our findings will hopefully 
stimulate further translational research efforts as, 
although a systematic review and meta-analysis44 found 
Figure 4: Quality-of-life scores in Rome IV functional dyspepsia subtypes according to (A) country and (B) 
health-care use
Error bars represent 95% CIs. SF8-PCS=short component score. SF8-MCS= SF8-mental component score. 
GI=gastrointestinal. *Overlapping groups had significantly worse scores than the postprandial distress syndrome 
group but not the epigastric pain syndrome group. †Overlapping groups had significantly worse scores than the 
postprandial distress syndrome group and the epigastric pain syndrome group. ‡All functional dyspepsia 
subtypes had significantly worse quality-of-life scores than controls without dyspepsia (p<0·0001). For all 
p values, see appendix.
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psychotropics (tricyclic anti depressants, antipsychotics, 
or both, but not selective serotonin reuptake inhibitors) to 
be more effective t han p lacebo f or t he t reatment o f 
functional dyspepsia (number needed to treat [NNT] 6), 
there is a paucity of high-quality randomised controlled 
trials, and which subtype of functional dyspepsia will 
benefit from psychotropics has not been elucidated.44 This 
is pertinent given that other treatment methods for 
functional dyspepsia are either restricted through 
concerns about their safety profile ( ie, p rokinetics) o r 
show modest benefit o nly ( ie, p roton-pump i nhibitors 
[NNT 13] and H pylori eradication [NNT 14]).45,46
Our findings might have important clinical and 
research implications as they bring into contention the 
published American College of Gastroenterology (ACG) 
and Canadian Association of Gastroenterology (CAG) 
joint guidelines on the management of dyspepsia.47 
The guidelines define dyspepsia as epigastric pain, and 
provide step-wise treatment recommendations including 
H pylori eradication, proton-pump inhibitors, tricylic 
anti depressants, and prokinetics.47 However, our study 
shows that across both countries, and in the UK, the 
predominant Rome IV functional dyspepsia subtype is 
by far postprandial distress syndrome (about 60%), 
which could imply that the ACG and CAG guidelines on 
dyspepsia might not necessarily be applicable to most 
individuals affected by functional dyspepsia within these 
countries. It then becomes unclear how such individuals 
with postprandial distress syndrome would be diagnosed 
or treated. Therapies for functional dyspepsia are modest 
at best and largely unsatisfactory for postprandial distress 
syndrome. For example, proton-pump inhibitors are 
ineffective for postprandial distress syndrome, and their 
unnecessary prescription would incur considerable cost 
Functional dyspepsia PDS EPS Overlapping PDS and EPS
AOR (95% CI) p value AOR (95% CI) p value AOR (95% CI) p value AOR (95% CI) p value
Decreasing age 1·01 (1·00–1·02) 0·027 1·00 (0·99–1·01) 0·444 1·02 (1·00–1·04) 0·017 1·03 (1·01–1·05) 0·017
Female 1·03 (0·83–1·27) 0·809 1·15 (0·89–1·48) 0·275 0·79 (0·50–1·25) 0·312 0·94 (0·55–1·58) 0·801
White 0·99 (0·79–1·25) 0·948 0·94 (0·72–1·23) 0·661 1·17 (0·70–1·96) 0·548 1·18 (0·67–2·10) 0·567
Relationship status
Single 1 ·· 1 ·· 1 ·· 1 ··
Married 0·97 (0·76–1·25) 0·833 1·11 (0·82–1·48) 0·490 0·66 (0·39–1·10) 0·112 0·85 (0·46–1·55) 0·590
Divorced 0·96 (0·65–1·41) 0·816 1·01 (0·64–1·59) 0·983 0·72 (0·32–1·63) 0·427 1·43 (0·59–3·45) 0·431
Widowed 1·17 (0·67–2·06) 0·575 1·13 (0·59–2·17) 0·711 0·55 (0·13–2·26) 0·405 1·39 (0·35–5·46) 0·640
Location
USA 1 ·· 1 ·· 1 ·· 1 ··
Canada 0·65 (0·51–0·83) 0·001 0·68 (0·51–0·90) 0·006 0·75 (0·44–1·26) 0·274 0·35 (0·19–0·66) 0·001




1·19 (0·95–1·50) 0·138 1·09 (0·83–1·42) 0·550 1·63 (0·99–2·69) 0·054 1·09 (0·63–1·88) 0·768
>1 health-care visits 
per year
1·11 (0·87–1·40) 0·403 1·19 (0·91–1·58) 0·192 0·95 (0·56–1·60) 0·833 1·25 (0·67–2·33) 0·488
Overlapping FGIDs
Functional heartburn 3·50 (2·14–5·74) <0·0001 2·46 (1·30–4·65) 0·006 3·18 (1·31–7·71) 0·011 7·05 (3·30–15·04) <0·0001
Irritable bowel 
syndrome
3·79 (2·83–5·07) <0·0001 1·63 (1·09–2·43) 0·017 6·43 (3·76–11·00) <0·0001 17·09 (9·80–29·81) <0·0001
Symptom scores
SF8-PCS 1·03 (1·02–1·04) <0·0001 1·02 (1·01–1·04) <0·0001 1·04 (1·01–1·06) 0·004 1·03 (1·01–1·06) 0·017
SF8-MCS 1·04 (1·03–1·05) <0·0001 1·04 (1·03–1·05) <0·0001 1·03 (1·01–1·06) 0·002 1·03 (1·01–1·06) 0·006
PHQ-12 somatisation 1·12 (1·10–1·16) <0·0001 1·12 (1·08–1·16) <0·0001 1·04 (0·97–1·12) 0·235 1·14 (1·07–1·22) <0·0001
Medication taken at least once a week
Antiemetic 1·60 (1·10–2·34) 0·015 1·58 (1·01–2·49) 0·046 1·29 (0·62–2·71) 0·492 2·01 (1·02–3·97) 0·044
Acid-suppressive 
medication
1·93 (1·52–2·44) <0·0001 1·53 (1·16–2·03) 0·003 2·83 (1·70–4·67) <0·0001 2·61 (1·49–4·57) 0·001
Analgesics 0·95 (0·75–1·20) 0·654 0·94 (0·71–1·24) 0·653 1·43 (0·85–2·41) 0·177 0·81 (0·45–1·44) 0·47
Antidepressant 0·63 (0·47–0·83) 0·001 0·61 (0·44–0·85) 0·003 0·57 (0·31–1·03) 0·062 0·72 (0·39–1·33) 0·299
AOR=adjusted odds ratio. PDS=postprandial distress syndrome. EPS=epigastric pain syndrome. PHQ-12=Patient Health Questionnaire-12 somatic symptom scale. 
SF8-PCS=short form-8 quality-of-life form-physical component score. SF8-MCS=SF8-mental component score. FGIDs=functional gastrointestinal disorders.
Table 3: Multivariate analysis evaluating the associations of participants with Rome IV functional dyspepsia and subtypes in comparison with individuals 
with no dyspepsia
and potential side-effects.48 Although H pylori eradication 
can help  with postprandial distress syndrome,49 as with 
epigastric pain syndrome, the prevalence of H pylori is 
on the decline among white Americans, which will 
conceivably render this approach less common.50,51 The 
role of antidepressants warrants further investigation 
within the functional dyspepsia subtypes, particularly 
for postprandial distress syndrome. Treatment with 
prokinetics is limited due to its significant adverse event 
profile. There is promising data for acotiamide, a 
first-in-class acetylcholinesterase inhibitor and musca-
rinic receptor agonist, to improve the symptoms of 
postprandial distress syndrome through accelerating 
gastric emptying and improving gastric accommodation; 
however, these findings are from a Japanese study, and 
are awaited in other populations.52 
In summary, there is currently little in the way of 
optimism for patients with functional dyspepsia in North 
America and Europe, especially those with postprandial 
distress syndrome, who represent the majority, because 
of an absence of effective therapeutic options. This is 
reflected by a questionnaire that calculated the mean cost 
of dyspepsia to patients as US$700 per year,6 and a study 
of the burden of gastrointestinal illness from the USA 
that reported almost two million physician visits in the 
year 2009 for dyspepsia.53 The economic and societal 
burden generated by individuals with functional 
dyspepsia was conservatively estimated to cost the USA at 
least $18·4 billion during 2009.6 Furthermore, individuals 
with functional dyspepsia are commonly under diagnosed 
in clinic, with only 12·5% of those with functional 
dyspepsia receiving the diagnosis.54 Instead, they are 
more likely to be classed as having gastro-oesophageal 
reflux disease, even if acid-suppressive therapy is 
unsuccessful.54 It is therefore imperative to raise 
awareness of the epidemiological scale of Rome IV 
functional dyspepsia and recognition of its subtypes, to 
aid future clinical service and research provision, and 
hopefully lead to guidelines and effective therapy 
addressing all functional dyspepsia subtypes.
The strength of our study is that it is the first to 
sample the prevalence of functional dyspepsia, using 
the Rome IV criteria,21 across a large sample of adults 
from three English-speaking countries, using the same 
systematic methodological process across countries. 
Moreover, we provide a comprehensive perspective on 
multiple characteristics seen in Rome IV functional 
dyspepsia and how they are independently associated 
with individual subtypes. It is logical to assume that, had 
our study been performed across multiple communities 
using the Rome III criteria, the prevalence would be 
expected to be similar to Rome IV, given that the main 
diagnostic criteria have remained unaltered by contrast 
with the historical Rome I or II iterations.4,21,55 However, 
no study has simultaneously evaluated the prevalence of 
functional dyspepsia across multiple communities using 
any of the previous Rome criteria.2 Instead, they have 
been limited to evaluations within single communities, 
which on pooling within their respective criteria have 
shown significant heterogeneity, irrespective of their 
geographical location.2 Hence, our study fills a void in 
the literature since the introduction of the Rome criteria 
almost 30 years ago.
The main limitation of our study is that the diagnosis 
of functional dyspepsia was based on fulfilling 
symptom-based criteria and was not subsequently 
confirmed by clinical evaluation or endoscopy. Our 
study could not feasibly perform endoscopy due to 
its widespread dissemination and internet basis. 
Furthermore, we did not ask participants whether they 
had previously undergone an endoscopy, because 
descriptive responses, particularly for endoscopic 
findings, would not be reliable and could not be verified. 
Hence, our participants can be termed as having 
uninvestigated dyspepsia. Nevertheless, we would argue 
that performing population-based endoscopic studies for 
epidemiological studies of dyspepsia within the North 
American and European population might no longer be 
necessary in view of its low diagnostic yield. In fact, 
three large population-based endoscopic studies9,26,27 have 
shown that most individuals with dyspepsia do not have 
organic pathology at endoscopy (>70%) and so will be 
diagnosed with functional dyspepsia, which supports our 
assumption. Furthermore, in those in whom organic 
pathology is noted, oesophagitis is among the most 
common finding (about 9% of all dyspepsia cases, 
therefore approximately a third of organic dyspepsia 
cases),26 but its role in causing dyspeptic symptoms is 
doubtful given that similar prevalence rates are seen in 
asymptomatic controls.56 The presence of peptic ulcer 
disease has been reported in about 9% and gastric cancer 
in up to about 2% in patients with dyspepsia.26,27 In this 
regard, the joint ACG and CAG guidelines acknowledge 
that gastric cancer is rare in individuals with dyspepsia 
presenting at younger than 60 years and thus do not 
routinely recommend upper gastrointestinal endoscopy 
as a first-line management plan in this group.47 Rather, 
they suggest to test and treat for H pylori, followed by 
treatment algorithms outlined for functional dyspepsia.47 
The UK National Institute for Health and Care Excellence 
has a similar policy of not recommending upper 
gastrointestinal endoscopy as a routine first-line test in 
those with dyspepsia younger than 55 years without 
alarm symptoms.57 Furthermore, our dataset is limited to 
three English-speaking countries and does not cover the 
epidemiology of functional dyspepsia globally. Our 
results therefore cannot be generalised to all countries. 
However, a global functional gastrointestinal disorder 
epidemiology study with comparable methodology is 
now underway and will help to address these issues. 
Another limitation of our study is that we sampled at 
a cross-sectional timepoint; however, longitudinal 
follow-up studies have shown that the prevalence of 
functional dyspepsia remains relatively stable over time.33
Finally, there are advantages and disadvantages to 
doing population-based surveys irrespective of whether 
this is through postal, face-to-face, telephone, or 
internet-based methods; these have been extensively 
discussed elsewhere for our dataset.18 This includes, on 
the one hand, the absence of a denominator, and on the 
other hand, the ability to reach large populations 
using cost-effective a nd t ime-effective me thods, 
performing quota-based sampling (for age, sex, and 
education) to obtain demographically balanced and 
nationally representative participants, building in 
quality assurance methods to ensure no missing data 
and eliminate inconsistent responders, and introducing 
the survey as one of general health without mention of 
gastrointestinal emphasis.18 Hence, despite method-
ological concerns regarding potential selection bias, we 
believe that necessary measures were undertaken to 
counteract this when possible and provide a representative 
epidemi ological profile across the three countries using a 
systematic and consistent methodology.18 Another issue 
worth noting is that the prevalence of functional dyspepsia 
has been recorded to be lower with internet surveys than 
with other methods of data collection.2 However, internet 
surveys in this field h ave b een l imited t o a  f ew s tudies 
and not subjected to broad historical definitions f or 
functional dyspepsia, which are generally associated with 
higher prevalence rates.2 It has also been speculated that 
personal approaches to collecting data, such as face-to-face 
or telephone surveys, might overestimate the prevalence 
of dyspepsia compared with more impersonal methods 
such as internet-based surveys.2
In conclusion, approximately 10% of the adult 
population from the USA, Canada, and the UK fulfil 
symptom-based criteria for Rome IV functional 
dyspepsia, and these individuals incur considerable 
health impairment. The factors associated with functional 
dyspepsia differ a ccording t o s ubtype, s uggesting 
different p athophysiological p rocesses o r i nfluences. 
These findings a re l ikely t o i ncrease a wareness o f t he 
epidemiological scale of functional dyspepsia in the 
general population and its detrimental effect on general 
health, and will hopefully aid clinical service and guide 
research planning, particularly in determining the role of 
antidepressants.
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